ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: 0.25mg MAP0010
Drug: Placebo
Drug: 0.135mg MAP0010

First Posted Date: 2007-12-07

Last Posted Date: 2014-01-09

Lead Sponsor: Allergan

Target Recruit Count: 360

Registration Number: NCT00569192

Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia

Phase 2

Completed

Conditions: Cervical Dystonia

Interventions: Biological: botulinum toxin type A
Biological: botulinum toxin type A Formulation 2
Drug: Normal Saline

First Posted Date: 2007-11-28

Last Posted Date: 2016-01-05

Lead Sponsor: Allergan

Target Recruit Count: 242

Registration Number: NCT00564681

A Study of 2 Doses of MAP0010 in Adult Asthmatics

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: MAP0010 low dose
Drug: MAP0010 high dose
Drug: Budesonide inhalation suspension 0.25mg
Drug: Budesonide inhalation suspension 0.5mg

First Posted Date: 2007-11-07

Last Posted Date: 2014-01-09

Lead Sponsor: Allergan

Target Recruit Count: 32

Registration Number: NCT00554970

Locations: 🇺🇸
West Coast Clinical Trials Phase 2-4, LLC, Long Beach, California, United States

BOTOX® Economic Spasticity Trial (BEST)

Phase 4

Completed

Conditions: Muscle Spasticity

Interventions: Biological: Botulinum Toxin Type A 900kD
Biological: Placebo

First Posted Date: 2007-10-26

Last Posted Date: 2012-08-22

Lead Sponsor: Allergan

Target Recruit Count: 274

Registration Number: NCT00549783

Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery

Not Applicable

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: Carboxymethylcellulose and Glycerin based artificial tear
Drug: Carboxymethylcellulose

First Posted Date: 2007-10-16

Last Posted Date: 2011-12-14

Lead Sponsor: Allergan

Target Recruit Count: 228

Registration Number: NCT00544713

Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Ocular Hypertension
Glaucoma

Interventions: Drug: bimatoprost 0.03% eye drops
Drug: latanoprost 0.005% eye drops

First Posted Date: 2007-10-10

Last Posted Date: 2011-10-27

Lead Sponsor: Allergan

Target Recruit Count: 586

Registration Number: NCT00541242

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

Phase 4

Completed

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: latanoprost 0.005% eye drops
Drug: Bimatoprost 0.03%
Drug: travoprost 0.004%

First Posted Date: 2007-10-04

Last Posted Date: 2019-04-24

Lead Sponsor: Allergan

Target Recruit Count: 106

Registration Number: NCT00539526

A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: bimatoprost eye drops
Drug: placebo

First Posted Date: 2007-10-02

Last Posted Date: 2019-04-23

Lead Sponsor: Allergan

Target Recruit Count: 222

Registration Number: NCT00538304

MDs on Botox Utility (MOBILITY)

Completed

Conditions: Muscle Spasticity
Strabismus
Blepharospasm
Torticollis

Interventions: Other: botulinum toxin type A

First Posted Date: 2007-09-27

Last Posted Date: 2014-09-10

Lead Sponsor: Allergan

Target Recruit Count: 1372

Registration Number: NCT00535938

Safety and Efficacy of AGN201781 in Neuropathic Pain

Phase 2

Terminated

Conditions: Neuralgia

Interventions: Drug: AGN201781
Drug: placebo

First Posted Date: 2007-09-21

Last Posted Date: 2016-02-24

Lead Sponsor: Allergan

Target Recruit Count: 9

Registration Number: NCT00533351

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy